CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Program Title

Sleep Solutions: Recognizing and Treating Insomnia
Release Date: March-30-07
Credit Expiration Date: August-21-08


Kathy P. Parker, PhD, RN, APRN, FAAN, Program Chair
Co-Director, Sleep Disorders Center
Professor, Nell Hodgson Woodruff School of Nursing
Emory University
Atlanta, GA

Nancy Nadolski, FNP, MSN, MEd, RN
Family Nurse Practitioner
Foothills Psychiatry
Boise, ID

Mary Adams, APRN, BC
Nurse Practitioner
Pulmonary Associates
Newark, DE

Teresa D. Valerio, MSA, MSN, APN, CNP
Advanced Practice Nurse, Certified Nurse Practitioner
OSF Saint Francis Sleep Disorders Center
Peoria, IL

Credit Hours

1 contact hour with 0.4 hours pharmacology


Online Presentation

Program Description

NOTE: This activity was originally presented as live AANP Group Lecture Series programs from March 30, 2007 through October 25, 2007. If you earned CE credit by attending an AANP Group Lecture Series program of the same title, you are not eligible to receive credit through this online release.

Insomnia is the most prevalent sleep disorder in the United States and is experienced by over 30% of the adult population at some point in time. The prevalence of insomnia increases with age and number of comorbidities; women are more susceptible. Because the U.S. population is aging, primary care providers will be increasingly challenged by patients experiencing insomnia and need to be properly educated on how to best treat this common, but often complex, problem.

Nurse practitioners (NPs) are crucial to the health care system as they diagnose and treat both acute and chronic health care problems. In addition, they act as pivotal advocates and educators for patients. Since their role in health care is growing, NPs need continuing education that focuses on recent, evidence-based guidelines and changes that may impact their practice. Thus, NPs practicing in a wide variety of settings should be familiar with ways to identify patients at risk for insomnia as well as its diagnosis and treatment. Knowledge of practical and cost-effective strategies designed to achieve this can be extremely useful for these busy practitioners and information regarding appropriate behavioral and pharmacologic therapies is essential.

Program Developer/Facilitator


Target Audience

This program was developed for nurse practitioners.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Identify insomnia as a health problem and explore the impact of insomnia on the patient, family, and society
  2. Discuss ways to identify patients who may be at risk for insomnia
  3. Evaluate barriers that impede recognition and treatment of insomnia
  4. Summarize current, evidence-based recommendations for the behavioral and pharmacologic treatment of insomnia
  5. Outline appropriate behavioral and pharmacologic strategies for the management of insomnia for patients experiencing specific types of insomnia


Kathy P. Parker discloses that she has received grant/research support from the National Institute of Nursing Research and has been a consultant for sanofi-aventis U.S.

Nancy Nadolski discloses that she has been a consultant for Takeda Pharmaceuticals North America, Inc., and a member of the speakerís bureau for sanofi-aventis U.S., Forest Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., Sepracor Inc., and Cephalon, Inc.

Mary Adams discloses that she has been a consultant for sanofi-aventis U.S. and a member of the speakerís bureau for Pfizer Inc, Genentech, Inc., and Novartis Pharmaceuticals Corporation.

Teresa D. Valerio has no conflicts of interest to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

Nurse Practitioner CE: This program has been approved for 1 contact hour with 0.4 hours pharmacology of continuing education for nurse practitioners by the American Academy of Nurse Practitioners. Program ID 0703141.

Commercial Support Statements

This activity is supported through an educational grant from sanofi-aventis.


  1. Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  2. Complete the short survey and click on "done."
  3. The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. This activity will require approximately 60 minutes to complete.
  4. After the program has finished, click on the "Post-test" button. Complete the short survey and click on "done."
  5. Instructions for completing and submitting the post-test and program evaluation are provided on the post-test screen. A credit certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.

Certificate Fee



The information contained in this program does not necessarily reflect the opinions or recommendations of sanofi-aventis, the American Academy of Nurse Practitioners, or Medical Communications Media, Inc. Diagnostic procedures or treatments discussed in the program should not be utilized by clinicians without evaluation of patientsí conditions and possible contraindications or risks, and without a review of applicable manufacturerís product information and comparison with recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu